Improving the effectiveness of treatment of patients with metabolic syndrome by the use of selenium and vitamin complex Oxylyc




metabolic syndrome, selenium, selenium and vitamin complex Oxylyc


Background. Metabolic syndrome (MS) affects about a quarter of the world population and is accompanied by abdominal obesity and insulin resistance, which are the factors of dyslipi­demia, hypertension and hyperglycemia. Nonthyroidal illness syndrome affects about 75 % of hospitalized patients and is accompanied by peripheral hypothyroidism due to inhibition of peripheral conversion of thyroid hormones. Due to the fact that about 80 % of thyroid hormones are produced in peripheral organs, and they regulate almost all processes in the body, the pathological changes that accompany nonthyroidal illness syndrome can be regarded significant. However, the effectiveness of vitamin complexes in combination with selenium in treatment of MS remains unknown. The purpose of the research was to study the effectiveness of Oxylyc in the comprehensive treatment of disorders of carbohydrate, lipid metabolism, endothelial function, antioxidant system, thyroid homeostasis in patients with metabolic syndrome. Materials and me­thods. Sixty-five patients were enrolled to the study. All patients were previously diagnosed with metabolic syndrome. To assess the effectiveness of treatment, patients were randomized into two groups. Patients of the first group (30 people) received Oxylyc — one capsule for 1 month on the background of basic treatment. Representatives of the second group (35 people) received basic treatment. Results. Additional administration of Oxylyc in treatment of patients with MS for 1 month leads to a significant improvement in the sensitivity of receptors to insulin, which is reflected in a decrease in HOMA-IR, indicators of the functional state of the endothelium (decreased production of vascular endothelial growth factor, and desquamation of endothelium), lipid metabolism (decrease in cholesterol, increase in high density lipoproteins and decrease in athe­rogenic coefficient, decrease in the titer of the free thyroxine (fТ4), increase in the free triiodothyronine (fТ3) and the ratio of fT3/fT4, which indicates an improvement of the peripheral conversion of thyroid hormones). Conclusions. Oxylyc can be recommended in comprehensive treatment of metabolic syndrome.


Download data is not yet available.


De Oliveira CM, Pavani J, Krieger JE, de Oliveira Alvim R, Mourão-Junior CA, da Costa Pereira A. Body adiposity index in assessing the risk of type 2 diabetes mellitus development: the Baependi Heart Study. Diabetol Metab Syndr. 2019;11:76. doi:10.1186/s13098-019-0467-1.

Cercato C, Fonseca FA. Cardiovascular risk and obesity. Diabetol Metab Syndr. 2019;11:74. doi:10.1186/s13098-019-0468-0.

Gupta D, Krueger CB, Lastra G. Over-nutrition, obesity and insulin resistance in the development of β-cell dysfunction. Curr Diabetes Rev. 2012;8(2):76–83. doi:10.2174/157339912799424564.

Shishkin AN, Lyndina ML. Endothelial dysfunction, metabolic syndrome and microalbuminuria. Nephrology. 2009;13(3):24–31. (in Russian).

Loebig M, Klement J, Schmoller A, et al. Evidence for a relationship between VEGF and BMI independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young men. PLoS One. 2010;5(9):e12610. doi:10.1371/journal.pone.0012610.

Schiapaccassa A, Maranhão PA, de Souza MDGC, et al. 30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and obesity: a randomized head-to-head metformin-controlled study. Diabetol Metab Syndr. 2019;11:70. doi:10.1186/s13098-019-0466-2.

Li R, Li W, Lun Z, et al. Prevalence of metabolic syndrome in Mainland China: a meta-analysis of published studies. BMC Public Health. 2016;16:296. doi:10.1186/s12889-016-2870-y.

Wajner SM, Maia AL. New Insights toward the Acute Non-Thyroidal Illness Syndrome. Front Endocrinol (Lausanne). 2012;3:8. doi:10.3389/fendo.2012.00008.

Wang B, Liu S, Li L, et al. Non-thyroidal illness syndrome in patients with cardiovascular diseases: A systematic review and meta-analysis. Int J Cardiol. 2017;226:1–10. doi:10.1016/j.ijcard.2016.10.039.

El-Ella SSA, El-Mekkawy MS, El-Dihemey MA. Prevalence and prognostic value of non-thyroidal illness syndrome among critically ill children. An Pediatr (Barc). 2019;90(4):237–243. doi:10.1016/j.anpedi.2018.01.021. (in Spanish).

Roman M, Jitaru P, Barbante C. Selenium biochemistry and its role for human health. Metallomics. 2014;6(1):25–54. doi:10.1039/c3mt00185g.

Bekarova AM. Breast-feeding. Consilium medicum. Pediatriia. 2009;(3):8–13. (in Russian).

Himoto T, Yoneyama H, Kurokohchi K, et al. Selenium deficiency is associated with insulin resistance in patients with hepatitis C virus-related chronic liver disease. Nutr Res. 2011;31(11):829–835. doi:10.1016/j.nutres.2011.09.021.

Smith AD, Cheung L, Beshah E, Shea-Donohue T, Urban JF Jr. Selenium status alters the immune response and expulsion of adult Heligmosomoides bakeri worms in mice. Infect Immun. 2013;81(7):2546–2553. doi:10.1128/IAI.01047-12.

Zhang Q, Qian ZY, Zhou PH, et al. Effects of oral selenium and magnesium co-supplementation on lipid metabolism, antioxidative status, histopathological lesions, and related gene expression in rats fed a high-fat diet. Lipids Health Dis. 2018;17(1):165. doi:10.1186/s12944-018-0815-4.

Farhangi MA, Keshavarz SA, Eshraghian M, Ostadrahimi A, Saboor-Yaraghi AA. The effect of vitamin A supplementation on thyroid function in premenopausal women. J Am Coll Nutr. 2012;31(4):268–274. doi:10.1080/07315724.2012.10720431.



How to Cite

Pashkovska, N., & Abramova, N. (2021). Improving the effectiveness of treatment of patients with metabolic syndrome by the use of selenium and vitamin complex Oxylyc. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 16(3), 221–226.



Original Researches

Most read articles by the same author(s)

1 2 3 4 > >>